ValiRx plc (AIM:VAL)

Market Cap	2.41M -0.8%
Revenue (ttm)	49.78K +418.5%
Net Income	-1.78M
EPS	-0.01
Shares Out	742.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	284,350
Average Volume	4,260,411
Open	0.3165
Previous Close	0.3250
Day's Range	0.3165 - 0.3165
52-Week Range	0.2200 - 0.8750
Beta	-0.67
RSI	45.66
Earnings Date	Apr 21, 2026

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.